The authors evaluate several ALS-associated mutations in OPTN's leucine-zipper domain but don't fully explain how these mutations mechanistically lead to disease pathogenesis. Understanding this link is critical for developing targeted ALS therapies. Gap type: unexplained_observation Source paper: Molecular Basis of the Recognition of the Active Rab8a by Optineurin. (2024, Journal of molecular biology, PMID:39374890)
Landscape Summary: How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and cellular function? is a 0.89 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
How do ALS-associated OPTN mutations mechanistically disrupt Rab8a binding and cellular function? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: